Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer
Abemaciclib combined with endocrine therapy improves OS in high-risk HR+, HER2− early breast cancer
Durvalumab combined with FLOT improves survival in resectable gastric and GEJ adenocarcinoma
NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL
Proton vs photon radiotherapy shows similar patient-reported quality of life in breast cancer patients
Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer
ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer
Non-clear cell renal cell carcinoma: Management of papillary RCC
Bladder cancer updates from the first half of 2025
CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression
WCLC 2025: Latest in EGFR positive NSCLC
Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours
Treatment management of favourable risk and very favourable risk patients